Catalyst Pharmaceuticals, Inc.
CPRX
$19.95
-$0.67-3.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 208.67M | 197.35M | 163.89M | 142.80M | 68.15M |
| Total Depreciation and Amortization | 37.83M | 37.80M | 37.77M | 37.46M | 36.58M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.79M | 261.00K | 7.23M | 10.20M | 88.07M |
| Change in Net Operating Assets | 24.81M | 32.51M | 30.91M | 34.12M | 4.04M |
| Cash from Operations | 275.09M | 267.93M | 239.81M | 224.58M | 196.84M |
| Capital Expenditure | -373.00K | -357.00K | -556.00K | -36.56M | -36.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -2.23M | -94.98M |
| Cash from Investing | -373.00K | -357.00K | -556.00K | -38.79M | -131.34M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.96M | 16.78M | 154.52M | 149.22M | 145.46M |
| Repurchase of Common Stock | -1.33M | -1.11M | -668.00K | -657.00K | -657.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13.24M | -13.00M | -13.18M | -13.00M | -13.39M |
| Cash from Financing | 2.39M | 2.68M | 140.67M | 135.57M | 131.41M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 277.11M | 270.25M | 379.92M | 321.36M | 196.91M |